Advertisement

Topics

A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma

2014-08-27 03:59:56 | BioPortfolio

Summary

To assess toxicity and determine the MTD of intravenous TNP-470 administered weekly in patients with AIDS-related Kaposi's sarcoma. To assess pharmacokinetics and tumor response of the drug.

Since evidence shows that neovascularization is important in the development of Kaposi's sarcoma, drugs that inhibit angiogenesis, such as TNP-470, may be of benefit in patients with the disease.

Description

Since evidence shows that neovascularization is important in the development of Kaposi's sarcoma, drugs that inhibit angiogenesis, such as TNP-470, may be of benefit in patients with the disease.

Patients are entered at 7 escalating dose levels of TNP-470. (PER AMENDMENT 9/3/96: dose maximum level changed.) Four patients treated at a given dose level must receive at least 4 weeks of therapy before escalation in subsequent cohorts proceeds. If 50 percent of patients at a given dose level experience dose-limiting toxicity, the previous dose is defined as the MTD and an additional two patients are treated at the MTD. Patients receive treatment for 12 weeks, followed by 2 weeks of rest, followed by an additional 12 weeks of treatment. Patients are followed for 12 weeks post-treatment.

Study Design

Control: Dose Comparison, Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment

Conditions

Sarcoma, Kaposi

Intervention

TNP-470

Location

Univ of Southern California / LA County USC Med Ctr
Los Angeles
California
United States
900331079

Status

Completed

Source

National Institute of Allergy and Infectious Diseases (NIAID)

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:59:56-0400

Clinical Trials [76 Associated Clinical Trials listed on BioPortfolio]

Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma

RATIONALE: Herpesvirus is found in the lesions of most patients with Kaposi's sarcoma, and may have a role in causing Kaposi's sarcoma. Valganciclovir is an antiviral drug that acts agains...

A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma

To evaluate the safety and effectiveness of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the long-term treatment of AIDS-related Kaposi's sarcoma (KS) in patients who previously...

A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma

To determine the safety and tolerance of interleukin-4 (IL-4) in patients with AIDS-related Kaposi's sarcoma. To determine the effects of IL-4 on tumor growth in patients with AIDS-related...

A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma

The purpose of this study is to see if ALRT1057 gel is safe and effective in treating Kaposi's sarcoma (KS) when applied to skin .

Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV Infection

RATIONALE: Herpesvirus is found in Kaposi's sarcoma lesions in most patients; it is therefore possible that the herpesvirus has a role in causing Kaposi's sarcoma. Cidofovir is an antivira...

PubMed Articles [52 Associated PubMed Articles listed on BioPortfolio]

Disseminated Kaposi Sarcoma with Epithelioid Morphology in an HIV/AIDS Patient; A Previously Unreported Variant.

Kaposi sarcoma is an oligoclonal HHV8-driven vascular proliferation that was first described in 1872 as an "idiopathic multiple pigmented sarcoma of the skin" by a Viennese dermatologist Dr. Moriz Kap...

El sarcoma de Kaposi es un tumor linfoangioproliferativo descripto por primera vez en el año 1872 por Moritz Kaposi. Hay cuatro variantes clínicas, la forma clásica, la endémica, la iatrogénica a...

Recurrent Kaposi sarcoma associated with Koebner phenomenon in two HIV-seronegative patients: Two case reports and a review of the literature.

Koebner phenomenon is occasionally reported in patients affected by classic Kaposi sarcoma (KS).

Evolution of Kaposi sarcoma in the past 30 years in a tertiary hospital of the European Mediterranean basin.

The incidence of Kaposi sarcoma (KS) has reduced as a result of the introduction of antiretroviral therapy. It is currently considered a rare disease in developed countries, and there has been a pauci...

Omega-3 decreases IL-6 levels in HIV and human herpesvirus-8 coinfected patients in Uganda.

Kaposi sarcoma is a HIV-associated malignancy caused by human herpesvirus-8 (HHV-8) that occurs at highest incidence in sub-Saharan Africa. Kaposi sarcoma patients often present with inflammatory symp...

Medical and Biotech [MESH] Definitions

A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.

A species in the genus RHADINOVIRUS, subfamily GAMMAHERPESVIRINAE, isolated from patients with AIDS-related and "classical" Kaposi sarcoma.

An experimental sarcoma of mice.

An experimental sarcoma of mice.

An experimental sarcoma of rats.

More From BioPortfolio on "A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...


Searches Linking to this Trial